Document is current
Any future updates will be listed below
-
Authors
Kang, Kaidi https://orcid.org/0000-0003-0922-5727
Seidlitz, Jakob https://orcid.org/0000-0002-8164-7476
Bethlehem, Richard A. I. https://orcid.org/0000-0002-0714-0685
Xiong, Jiangmei
Jones, Megan T. https://orcid.org/0000-0001-7999-7031
Mehta, Kahini
Keller, Arielle S. https://orcid.org/0000-0003-4708-1672
Tao, Ran
Randolph, Anita
Larsen, Bart
Tervo-Clemmens, Brenden
Feczko, Eric
Dominguez, Oscar Miranda
Nelson, Steven M.
,
Alexander-Bloch, Aaron F.
Fair, Damien A.
Schildcrout, Jonathan
Fair, Damien A. https://orcid.org/0000-0001-8602-393X
Satterthwaite, Theodore D. https://orcid.org/0000-0001-7072-9399
Alexander-Bloch, Aaron https://orcid.org/0000-0001-6554-1893
Vandekar, Simon https://orcid.org/0000-0002-7457-9073
- License Information
-
More Information
Article History
Received: 27 May 2023
Accepted: 21 October 2024
First Online: 27 November 2024
Competing interests
: J.Seidlitz and R.A.I.B. are directors and hold equity in Centile Bioscience. A.A.-B. holds equity in Centile Bioscience and received consulting income from Octave Bioscience in 2023. S.M.N. consults for Turing Medical, which commercializes FIRMM. This interest has been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies. All other authors declare no competing interests.
